Recon: Pfizer posts positive Phase 3 data for RSV vaccine in adults 18 and older; Novartis to cut 680 product development jobs

• Pfizer’s plot to win the RSV vaccine race (STAT) (Endpoints)
• Pfizer RSV shot meets goals in trial of high-risk adults under age 60 (Reuters)
• BrainStorm outlines plans for what may be final attempt to bring ALS drug to market (Endpoints)
• Over a year after biosimilars started competing, AbbVie still holds 96% of Humira market, report says (Endpoints)
• As FDA weighs another myeloma endpoint for accelerated approvals, experts say timely access is at stake (Fierce Pharma)
• Moderna jumps as vaccine shows benefit in head and neck cancer in early study (Reuters)

• Novartis to cut 680 jobs in product development (Reuters)
• Model Contract To Expedite UK Clinical Trial Negotiations Between Non-Commercial Sponsors & Companies (Pink Sheet)
• EU Health Experts On How ‘Optimization’ Could Improve Benefit Of New Cancer Drugs (Pink Sheet)
• Why Vital EU Guidance For Clinical Investigation Plans Is So Challenging To Read (MedTech Insight)
• UK Body Proposes Contract To Expedite Clinical Trials (MedTech Insight)

• Biotech startups post strongest financing numbers in two years (STAT)
• Big biotech names roll out Seaport Therapeutics, as interest in neuropsychiatric drugs swells (STAT)
• Acrivon draws in $130M; Vincerx Pharma's Ph1 metastatic tumor data (Endpoints)
• Monsters, dinosaurs and superheroes: Why pharma is bringing characters back into the ad mix (Endpoints)
• Two ex-bluebird leaders launch Nvelop with $100M to tackle the biggest problem in gene editing (Endpoints)
• MarketingRx roundup: Study finds generic drugs gain ground, but docs still prefer brands; Pfizer lauded at AACR (Endpoints)
• Updated: Steve Paul, Daphne Zohar reunite for another neuro startup after Karuna success (Endpoints)
• CG Life adds Toolhouse to portfolio, snapping up digital agency to double in size (Fierce Pharma)
• Advanced therapy CDMO Ascend nabs Florida manufacturing site and team from ocular gene therapy outfit Beacon (Fierce Pharma)
• AACR: Detailed data spark glimmer of hope for Merck's Keytruda-Lynparza combo in lung cancer (Fierce Pharma)

• MassMutual is rolling out free genetic testing for members, a dicey area for life insurers (STAT)
• Device made by company J&J is buying for $13 billion clears hurdle in independent study (STAT)
• New liquid biopsy screening test for pancreatic cancer shows promise in early data (STAT)
• Exclusive: Digital health venture firm Define Ventures hires industry vet Frank Williams (Endpoints)
• UPDATED: Thermo Fisher plots 74 layoffs at California plasmid manufacturing site as demand swings (Fierce Pharma)

• Medicaid redetermination cost community health centers an average of $600K each (STAT)
• HCA’s charity care filings are on hyperdrive (STAT)
• US says SK Battery faces $77,200 in fines over employee health hazards (Reuters)
• FDA slams Jubilant Generics, Canada's Contract Pharmaceuticals with Form 483s (Fierce Pharma)
• UPDATED: In refiling $16.5B Catalent buyout pitch, Novo gives FTC more time for review (Fierce Pharma)